1. Home
  2. SNSC vs BMEA Comparison

SNSC vs BMEA Comparison

Compare SNSC & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SNSC

SunScout Holding Limited Class A Ordinary Shares

N/A

Current Price

$0.94

Market Cap

39.2M

Sector

N/A

ML Signal

N/A

Logo Biomea Fusion Inc.

BMEA

Biomea Fusion Inc.

HOLD

Current Price

$0.60

Market Cap

42.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SNSC
BMEA
Founded
1998
2017
Country
New Zealand
United States
Employees
N/A
37
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
39.2M
42.4M
IPO Year
2026
2021

Fundamental Metrics

Financial Performance
Metric
SNSC
BMEA
Price
$0.94
$0.60
Analyst Decision
Buy
Analyst Count
0
8
Target Price
N/A
★ $6.57
AVG Volume (30 Days)
30.7K
★ 2.2M
Earning Date
11-19-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 69.19
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.82
$0.58
52 Week High
$3.15
$2.24

Technical Indicators

Market Signals
Indicator
SNSC
BMEA
Relative Strength Index (RSI) 31.71 22.67
Support Level $0.82 N/A
Resistance Level $1.14 $1.47
Average True Range (ATR) 0.15 0.11
MACD 0.01 -0.06
Stochastic Oscillator 28.26 2.92

Price Performance

Historical Comparison
SNSC
BMEA

About SNSC SunScout Holding Limited Class A Ordinary Shares

SunScout Holding Ltd is a clean-technology company engaged in the design, development, manufacturing, and commercialization of autonomous, solar-powered robotic mowers and related solar energy solutions. Its products are intended as alternatives to petrol-powered and grid-dependent electric lawn mowing equipment. The company's business comprises three lines of products and solutions, which are also its reportable segments: SunScout Products, Solar Power Development Solutions, and Engineering Products and Services. The majority of revenue is derived from the Solar Power Development Solutions segment, which develops and installs solar-energy systems for commercial, industrial, and institutional customers through EPC contracts. Geographically, maximum revenue is derived from New Zealand.

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.

Share on Social Networks: